Author stories Proactiveinvestors Author stories RSS feed en Sat, 20 Jan 2018 11:35:42 +0000 Genera CMS (Proactiveinvestors) (Proactiveinvestors) CUI Global to work with France’s ENGIE for GasPT and VE Technology Tue, 14 Mar 2017 17:02:00 +0000 Bacanora grants stock options, shares rise Fri, 03 Mar 2017 18:47:00 +0000 SEC launches insider trading probe of Fortress Inv Grp takeover Wed, 01 Mar 2017 13:41:00 +0000 Alba signs deal to acquire 50% of Noram claims Wed, 22 Feb 2017 19:09:00 +0000 Mkango says all AGM business approved Mon, 20 Feb 2017 17:32:00 +0000 CUI Global UK unit lands BioMethane contract worth over $750,000 Tue, 14 Feb 2017 18:53:00 +0000 Eco Atlantic publishes AIM admission papers with £4.8mln conditional placement Fri, 03 Feb 2017 16:17:00 +0000 Mandalay drills 7.78 m of 65.55 g/t Au at Bjorkdal, provides six months update Fri, 27 Jan 2017 18:58:00 +0000 Copper advances 3% on Chile strike risk Tue, 24 Jan 2017 19:35:00 +0000 Anglo-Saxon economies benefit from Brexit, Trump, says BlackRock’s Fink Fri, 20 Jan 2017 14:29:00 +0000 Midatech chief talks Zuplenz launch and 2015 sales beat Drug delivery specialist Midatech Pharma PLC’s (LON:MTPH) will commercially launch Zuplenz, its anti-vomiting drug for chemo and radiotherapy patients, in the US this week.

The drug maker acquired the treatment from Galena Biopharma in December and Jim Phillips, chief executive, tells Proactive that he expected the product “could reach peak sales of somewhere between 20 and 30 million dollars a year”.

The firm also reported full year results for 2015, with revenue of £1.38mln ahead of expectations of £1.21mln.

Phillips says the results were ahead of expectations, adding “it is nice to be able to outperform in our first full year in the market.”

Wed, 13 Apr 2016 08:33:00 +0100
Nasstar boosts pre-tax profits on acquisition synergies Nasstar Plc (LON:NASA), the cloud service provider, increased adjusted pre-tax profit in 2015 and that is thanks to benefits of integrating acquisitions, its chief executive Nigel Redwood tells Proactive Investors.

Nasstar is cautious not to make acquisitions for growth alone and seeks key strategic justifications. Its most recent acquisition, VESK, in late 2015, the company found several benefits, including James Mackie, the founder whom Redwood was keen to get on board and has appointed Group Sales Director.

But organic growth is also important to the future of the business. “Hence, in 2016 we are putting a lot of investment into sales and marketing. To re-launch under one umbrella brand name which will be Nasstar,” he says.

To learn about Nasstar, visit its website:

Tue, 12 Apr 2016 10:06:00 +0100
CEO: Summit Therapeutics’ ridinilazole generating “huge interest” from industry experts Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) says the results from its Phase II trial for its treatment for super-bug C- diff was “just about as good as we could have expected and dreamed of,” adding that it is generating “a huge amount of interest” from C-difficile experts.

Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.

Summit said the findings show a reduced recurrence rate and a superior rate of sustained clinical response in patients with C-diff receiving its treatment ridinilazole, compared with those receiving the standard of care, vancomycin.

Tue, 12 Apr 2016 15:00:00 +0100
Iofina chief “pleasantly pleased” with first quarter production performance Tom Becker, chief executive of Iofina PLC (LON:IOF), says the company’s iodine production in the first quarter “was pretty much right on what he had anticipated to do”.

The company, which extracts iodine from waste brine water from oil production in the US, said on Monday that output for the first quarter was 124.6 metric tonnes (MT).

Becker tells Proactive he is “pleasantly pleased” with the production figures and confirms Iofina remains “right on track to hit our production targets”.

Mon, 11 Apr 2016 15:30:00 +0100
KEFI on track for gold output at Tulu Kapi by end 2017 KEFI Minerals PLC (LON:KEFI) is on track to begin gold production at Tulu Kapi in Ethiopia at the end of 2017, executive chairman Harry Adams tells Proactive Investors.

Meanwhile, Kefi has been working with its seven syndicate financing partners over the past 18 months, and Adams says “it’s a process we have to go through to make sure parties are comfortable and aligned.”

KEFI has also been talking to regulators in Saudi Arabia regarding a licence application for the Jibal Qutman site.

Although progress is slow, Adams says it “doesn’t harm KEFI which has its hands full at Tulu Kapi. Saudi Arabia is a much larger play for KEFI. We believe we’ve pegged an emerging province not just a project. We are starting by focusing on the development of one particular licence. At Jibal Qutman we have made a gold discovery,” Adams says.

Mon, 11 Apr 2016 13:13:00 +0100
Central Asia Metals shows confidence with divi pay-out says chief Nick Clarke, chief executive of Central Asia Metals Ltd (LON:CAML) says by paying a dividend, the company is showing it has confidence in its “future production, future costs of production and the commodity price going forward”.

The company has now paid back more in dividends than it raised in its initial public offering, saying the milestone was “pretty unique”, adding that it gave the company “a strong following from the investment community”.

He spoke after the firm released 2015 results, which showed the company sold a record 12,040 tonnes of copper from its Kounrad project in Kazakhstan, to generate revenue of US$67.3mln.

Mon, 11 Apr 2016 11:41:00 +0100
Metal Tiger boss “hugely excited” by Bostwana mine Paul Johnson, chief executive of Metal Tiger plc (LON:MTR), says he is “hugely excited” by the potential of the group’s mine in Botswana.
“There are various interesting signs coming from the drilling so far,” he told Proactive Investors.
Although the focus at the Botswana mine remains on silver and copper, drilling has identified a range of mineralisation, “there’s a possibility we might be onto something really substantial.”
He said the team in Botswana was “pushing ahead as hard and as fast as we can,” and investors are to expect more data to be released in the near future.
Regarding the recent dip in share price he said: “you have to accept these things, the market doesn’t always keep track with reality.”

Fri, 08 Apr 2016 16:03:00 +0100
Minds + Machines focuses on China domain launch in May Minds + Machines Group Ltd (LON:MMX) believes that outsourcing two of its three business areas in the top level internet domain space means it can focus on the high value part it retains.

Speaking to Proactive Investors, Minds chief executive Toby Hall says only non-core areas have been transferred to Nominet and UniRegistry and that no further outsourcing is anticipated.

“We are still left with an exceptional portfolio of assets. We have landmark cities in our portfolio [such as .London],” he says.

Hall says that the next development for the company is the launch of its first domain on May 17 (London dateline)  in China. “It is a significant market,” he says.

The industry at large will also face more consolidation this year as companies that have not performed so well could become ripe opportunities for acquisition by Minds + Machines.

Fri, 08 Apr 2016 15:57:00 +0100
Sunrise Resources boss says mining sector at a “turning point” Sunrise Resources PLC chairman Patrick Cheetham (LON:SRES) tells Proactive Investors that Nevada is a “great place to be looking for gold”.

Surface and underground sampling on an area to the south of the existing exploration plots continue at the Bay State silver project, Nevada, in preparation for follow-up drilling expected in the summer.

Earlier this week, Cheetham backed Sunrise’s latest placing, taking his stake to 8.61%, and the chief executive says he thinks the mining sector “is at the turning point”, adding that this year will be “an interesting time for the company”.

Fri, 08 Apr 2016 13:44:00 +0100
Silence Therapeutics boss very pleased with latest drug results Silence Therapeutics PLC (LON:SLN OTCMKTS:SLNCF) chief executive Ali Mortazavi told investors this week its flagship drug has the potential to become a new oncology treatment.

This followed the publication of detailed findings from its long-awaited phase IIa clinical trial.

Speaking to Proactive, Mortazavi says the company received “the best possible result given the number of patients with statistically significant hints of efficacy in the metastatic cohort”.

Fri, 08 Apr 2016 13:17:00 +0100